摘要
Although chimeric antigen receptor(CAR)T cell therapy has shown incredible success in treating hematological malignancies,its application in solid tumors is unsatisfactory owing to the harsh physical barriers and immunosuppressive microenvironment.The ideal CAR T therapy will require a novel armored CAR T cell engineered to navigate the circulatory system,penetrate tumor tissues,and survive in the harsh tumor microenvironment to exert an adequate immune effect.
